

10/824,917

=> .....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840



L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED



=>

Uploading C:\STNEXP4\QUERIES\10824917 (dr).str



Hy<sup>2</sup>

19<sup>2</sup>



chain nodes :  
7 8 9 10 11 12 19 24 25  
ring nodes :  
1 2 3 4 5 6 13 14 15 16 17 18  
chain bonds :  
1-25 3-9 4-7 5-8 9-10 9-11 11-12 12-24  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18  
exact/norm bonds :  
1-2 1-6 1-25 2-3 3-4 4-5 4-7 5-6 5-8 9-10 9-11 11-12 12-24  
exact bonds :  
3-9  
normalized bonds :  
13-14 13-18 14-15 15-16 16-17 17-18  
isolated ring systems :  
containing 1 :

G1:[\*1],[\*2]

Match level :

10/824,917

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
24:CLASS 25:Atom

Generic attributes :

19:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : less than 2

Type of Ring System : Monocyclic

25:

Saturation : Unsaturated

Element Count :

Node 19: Limited

C,C5

N,N1

O,O0

S,S0

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d 14

L4 HAS NO ANSWERS

L1 SCR 1840

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s 14 sss sam

SAMPLE SEARCH INITIATED 16:36:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 108 TO ITERATE

100.0% PROCESSED 108 ITERATIONS

20 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1537 TO 2783

PROJECTED ANSWERS: 132 TO 668

L5 20 SEA SSS SAM L3 AND L1 NOT L2

=> => ....Testing the current file.... screen

10/824,917

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840



L6 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10824917 (drl).str



Hy<sup>2</sup>

19<sup>2</sup>

Hy<sup>3</sup>



27<sup>3</sup>

Hy<sup>4</sup>

28<sup>4</sup>

Hy<sup>5</sup>

29<sup>5</sup>



chain nodes :

7 8 9 10 11 12 19 24 25 27 28 29

ring nodes :

1 2 3 4 5 6 13 14 15 16 17 18

chain bonds :

1-25 3-9 4-7 5-8 9-10 9-11 11-12 12-24

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

1-2 1-6 1-25 2-3 3-4 4-5 4-7 5-6 5-8 9-10 9-11 11-12 12-24

exact bonds :

3-9

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18

isolated ring systems :

containing 1 :

G1:[\*1],[\*2]

G2:[\*1],[\*2],[\*3],[\*4],[\*5]

10/824,917

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
24:CLASS 25:Atom 27:Atom 28:Atom 29:Atom

Generic attributes :

19:

Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : less than 2  
Type of Ring System : Monocyclic

27:

Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : less than 2  
Type of Ring System : Monocyclic

28:

Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : less than 2  
Type of Ring System : Monocyclic

29:

Saturation : Unsaturated  
Number of Hetero Atoms : 2 or more  
Type of Ring System : Polycyclic

Element Count :

Node 19: Limited

C,C5  
N,N1  
O,O0  
S,S0

Node 27: Limited

C,C4  
N,N1  
O,O0  
S,S0

Node 28: Limited

C,C4  
O,O1  
N,N0  
S,S0

Node 29: Limited

N,N3  
C,C6  
O,O0  
S,S0

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

10/824,917

L9 QUE L8 AND L6 NOT L7

=> d 19

L9 HAS NO ANSWERS

L6 SCR 1840

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L8 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

L9 QUE L8 AND L6 NOT L7

=> s 19 sss sam

SAMPLE SEARCH INITIATED 16:41:50 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 106 TO ITERATE

100.0% PROCESSED 106 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1503 TO 2737

PROJECTED ANSWERS: 8 TO 329

L10 8 SEA SSS SAM L8 AND L6 NOT L7

=> => s 19 sss ful

FULL SEARCH INITIATED 16:43:53 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2031 TO ITERATE

100.0% PROCESSED 2031 ITERATIONS

218 ANSWERS

SEARCH TIME: 00.00.01

L11 218 SEA SSS FUL L8 AND L6 NOT L7

=> => s 111

L12 2 L11

=> d 112 1-2 bib,ab,hitstr

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:334912 CAPLUS  
 DN 138:354001  
 TI Preparation of N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase  
 IN Crescenzi, Benedetta; Gardelli, Cristina; Muraglia, Ester; Nizi, Emanuela; Orvieto, Federica; Pace, Paola; Pescatore, Giovanna; Petrocchi, Alessia; Poma, Marco; Rowley, Michael; Scarpelli, Rita; Summa, Vincenzo  
 PA Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Italy  
 SO PCT Int. Appl., 217 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035077	A1	20030501	WO 2002-GB4753	20021021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1441735	A1	20040804	EP 2002-801950	20021021
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	US 2001-339568P	P	20011026		
	US 2002-362191P	P	20020306		
	WO 2002-GB4753	W	20021021		
OS	MARPAT 138:354001				
AB	Title compds. I [R1 = H, alkyl, etc.; R2 = alkyl; R3 = H, alkyl; R4 = H, alkyl, alkynyl, etc.] are prepared For instance, 5-[(2,2-dimethylpropanoyl)oxy]-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxylate (general procedures provided for preparation) is reacted with 4-fluorobenzylamine (DMF, 90°, 2 h) to yield II. I are inhibitors of HIV integrase and inhibitors of HIV replication and are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. I can be employed in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.				
IT	<b>518047-27-3P</b> , N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide <b>518047-34-2P</b> , N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-[4-((morpholinyl)methyl)phenyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide <b>518048-25-4P</b> , N-(2-Ethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide <b>518048-26-5P</b> , N-(2,3-Dimethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide <b>518048-27-6P</b> , N-(2,3-Dimethoxybenzyl)-2-[4-[(dimethylamino)methyl]phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide <b>518048-28-7P</b> <b>518048-29-8P</b> , N-(4-Fluorobenzyl)-2-[4-[(dimethylamino)methyl]phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-				

dihydropyrimidine-4-carboxamide **518048-30-1P**  
**518048-31-2P**, N-(2,3-Dimethoxybenzyl)-5-hydroxy-1-methyl-6-oxo-2-[4-(pyrrolidin-1-ylmethyl)phenyl]-1,6-dihydropyrimidine-4-carboxamide  
**518048-32-3P 518048-33-4P**, N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-[4-((pyrrolidin-1-yl)methyl)phenyl]-1,6-dihydropyrimidine-4-carboxamide **518048-34-5P 518048-35-6P**,  
 N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-[4-((piperidinyl)methyl)phenyl]-1,6-dihydropyrimidine-4-carboxamide  
**518048-36-7P 518048-37-8P**, N-(2,3-Dimethoxybenzyl)-5-hydroxy-1-methyl-2-[4-((morpholinyl)methyl)phenyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide **518048-38-9P**  
**518048-39-0P 518048-40-3P**, N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide **518048-41-4P**  
**518048-42-5P**, 2-[4-[(Diethylamino)methyl]phenyl]-N-(2,3-dimethoxybenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide **518048-43-6P 518048-44-7P**,  
 2-[4-[(Diethylamino)methyl]phenyl]-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide **518048-45-8P**  
**518048-54-9P**, 1-[2-(Dimethylamino)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-2-(2-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide  
**518048-55-0P 518048-58-3P**, 2-[4-[(4-Ethylpiperazin-1-yl)methyl]phenyl]-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide **518048-59-4P**  
**518048-60-7P**, N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-[4-[(2-pyridin-3-yl)piperidinyl)methyl]phenyl]-1,6-dihydropyrimidine-4-carboxamide **518048-61-8P 518048-67-4P**,  
 (R)-N-(4-Fluorobenzyl)-5-hydroxy-2-[4-[[2-(methoxymethyl)pyrrolidin-1-yl]methyl]phenyl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide  
**518048-68-5P 518048-69-6P**, (S)-N-(4-Fluorobenzyl)-5-hydroxy-2-[4-[[2-(methoxymethyl)pyrrolidin-1-yl]methyl]phenyl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide **518048-70-9P**  
**518048-71-0P**, N-(4-Fluorobenzyl)-2-[4-[[4-(4-fluorobenzyl)amino]methyl]phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide **518048-72-1P**  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase)


RN 518047-27-3 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 518047-34-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 518048-25-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 518048-26-5 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 518048-27-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-2-[4-[(dimethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)






RN 518048-28-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-2-[4-[(dimethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-27-6


CMF C24 H28 N4 O5



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 518048-29-8 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(dimethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 518048-30-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(dimethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-29-8


CMF C22 H23 F N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 518048-31-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-

10/824,917

hydroxy-1-methyl-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 518048-32-3 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-31-2


CMF C26 H30 N4 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-33-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 518048-34-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-33-4


CMF C24 H25 F N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 518048-35-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)


10/824,917



RN 518048-36-7 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 518048-35-6  
CMF C25 H27 F N4 O3




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 518048-37-8 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)


10/824,917



RN 518048-38-9 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 518048-37-8  
CMF C26 H30 N4 O6



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 518048-39-0 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 518047-34-2  
CMF C24 H25 F N4 O4

10/824,917




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 518048-40-3 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 518048-41-4 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 518048-40-3  
CMF C25 H28 F N5 O3




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 518048-42-5 CAPLUS  
CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 518048-43-6 CAPLUS  
CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-42-5  
CMF C26 H32 N4 O5




10/824,917



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-44-7 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)



RN 518048-45-8 CAPLUS


CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-44-7

CMF C24 H27 F N4 O3


10/824,917



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-54-9 CAPLUS

CN 4-Pyrimidinecarboxamide, 1-[2-(dimethylamino)ethyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo- (9CI)  
(CA INDEX NAME)




RN 518048-55-0 CAPLUS

CN 4-Pyrimidinecarboxamide, 1-[2-(dimethylamino)ethyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-54-9


CMF C23 H25 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-58-3 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 518048-59-4 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-58-3


CMF C26 H30 F N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-60-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-[[2-(3-pyridinyl)-1-piperidinyl]methyl]phenyl]- (9CI)  
(CA INDEX NAME)



RN 518048-61-8 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-[[2-(3-pyridinyl)-1-piperidinyl]methyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-60-7

CMF C30 H30 F N5 O3


10/824,917



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 518048-67-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]phenyl]-1-methyl-6-oxo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 518048-68-5 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]phenyl]-1-methyl-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

10/824,917


CRN 518048-67-4  
CMF C26 H29 F N4 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 518048-69-6 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-  
2-[4-[[ (2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]phenyl]-1-methyl-6-oxo-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/824,917




RN 518048-70-9 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]phenyl]-1-methyl-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-69-6  
CMF C26 H29 F N4 O4


Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2

10/824,917



RN 518048-71-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-2-[4-[[[(4-fluorophenyl)methyl]amino]methyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 518048-72-1 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-2-[4-[[[(4-fluorophenyl)methyl]amino]methyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 518048-71-0


CMF C27 H24 F2 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2





10/824,917

RE.CNT 5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:334911 CAPLUS

DN 138:354000

TI Preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase

IN Di Francesco, Maria Emilia; Gardelli, Cristina; Harper, Steven; Matassa, Victor Giulio; Muraglia, Ester; Nizi, Emanuela; Pace, Paola; Pacini, Barbara; Petrocchi, Alessia; Poma, Marco; Summa, Vincenzo

PA Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Italy

SO PCT Int. Appl., 315 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035076	A1	20030501	WO 2002-GB4742	20021021
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1441734	A1	20040804	EP 2002-801949	20021021
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
PRAI	US 2001-348195P	P	20011026		
	WO 2002-GB4742	W	20021021		

OS MARPAT 138:354000

AB The title 4,5-dihydroxypyrimidine-6-carboxamides [I; R1 = H, alkyl, haloalkyl, alkoxy, etc.; R2 = H, alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = H, alkyl; R4 = H, alkyl, haloalkyl, etc.] which are inhibitors of HIV integrase and inhibitors of HIV replication, and therefore are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS, were prepared. Thus, refluxing N-hydroxythiophene-2-carboximidamide with di-Me acetylenedicarboxylate in CHCl<sub>3</sub> followed by reacting the resulting Me 5,6-dihydroxy-2-(2-thienyl)pyrimidine-4-carboxylate with 4-fluorobenzylamine in DMF afforded I [R1 = 2-thienyl; R2 = H; R3 = 4-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>; R4 = H]. The compds. I are employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. I and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

IT 519023-55-3P 519023-56-4P 519023-57-5P  
 519023-58-6P 519023-59-7P 519023-60-0P  
 519023-61-1P 519023-62-2P 519023-63-3P  
 519023-64-4P 519023-65-5P 519023-66-6P  
 519023-68-8P 519023-69-9P 519023-70-2P  
 519023-71-3P 519023-72-4P 519023-73-5P  
 519023-75-7P 519023-79-1P 519023-80-4P  
 519023-82-6P 519023-83-7P 519023-85-9P  
 519023-86-0P 519023-87-1P 519023-88-2P  
 519023-89-3P 519023-90-6P 519023-91-7P


519023-92-8P 519023-93-9P 519023-95-1P  
 519023-96-2P 519023-97-3P 519023-98-4P  
 519023-99-5P 519024-02-3P 519024-04-5P  
 519024-05-6P 519024-07-8P 519024-08-9P  
 519024-09-0P 519024-11-4P 519024-13-6P  
 519024-14-7P 519024-15-8P 519024-16-9P  
 519024-19-2P 519024-20-5P 519024-22-7P  
 519024-24-9P 519024-26-1P 519024-28-3P  
 519024-30-7P 519024-32-9P 519024-33-0P  
 519024-35-2P 519024-37-4P 519024-38-5P  
 519024-39-6P 519024-40-9P 519024-41-0P  
 519024-43-2P 519024-45-4P 519024-47-6P  
 519024-49-8P 519024-51-2P 519024-53-4P  
 519024-54-5P 519024-55-6P 519024-57-8P  
 519024-59-0P 519024-61-4P 519024-63-6P  
 519024-65-8P 519024-67-0P 519024-68-1P  
 519024-69-2P 519024-70-5P 519024-71-6P  
 519024-72-7P 519024-73-8P 519024-75-0P  
 519024-77-2P 519024-79-4P 519024-81-8P  
 519024-83-0P 519024-85-2P 519024-87-4P  
 519024-89-6P 519024-91-0P 519024-92-1P  
 519024-93-2P 519024-95-4P 519024-97-6P  
 519024-99-8P 519025-01-5P 519025-02-6P  
 519025-03-7P 519025-04-8P 519025-05-9P  
 519025-07-1P 519025-09-3P 519025-11-7P  
 519025-13-9P 519025-14-0P 519025-15-1P  
 519025-16-2P 519025-17-3P 519025-18-4P  
 519025-19-5P 519025-21-9P 519025-22-0P  
 519025-23-1P 519025-25-3P 519025-27-5P  
 519030-68-3P 519030-69-4P 519030-70-7P  
 519030-71-8P 519030-72-9P 519030-73-0P  
 519030-74-1P 519030-75-2P 519030-76-3P  
 519030-77-4P 519030-79-6P 519030-81-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase)


RN 519023-55-3 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo-N-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 519023-56-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-  
 2-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519023-57-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519023-58-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519023-59-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519023-60-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519023-61-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-N-[(3-methoxyphenyl)methyl]-2-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519023-62-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-difluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519023-63-3 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,4-difluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519023-64-4 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 519023-65-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(2-pyridinylcarbonyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 519023-66-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519023-68-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-phenyl- (9CI) (CA INDEX NAME)



RN 519023-69-9 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(4-pyridinylcarbonyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 519023-70-2 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2-[[[(2,3-dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519023-71-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[1,4-dihydro-5-hydroxy-4-oxo-6-[(phenylmethyl)amino]carbonyl]-2-pyrimidinyl]phenyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 519023-72-4 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-2-[2-(1-




10/824,917

naphthalenylmethoxy)phenyl]-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519023-73-5 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2-[[[(2,5-dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 519023-75-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(3-pyridinylcarbonyl)amino]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519023-74-6


CMF C26 H23 N5 O6



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 519023-79-1 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(3-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519023-80-4 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(3-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519023-82-6 CAPLUS  
 CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[3-(4-morpholinylmethyl)phenyl]-6-oxo-, trifluoroacetate (salt) (9CI)  
 (CA INDEX NAME)


CM 1

CRN 519023-81-5  
 CMF C23 H23 F N4 O4




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 519023-83-7 CAPLUS  
 CN 4-Pyrimidinecarboxamide, N-[(3-chlorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(3-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519023-85-9 CAPLUS  
 CN 4-Pyrimidinecarboxamide, 2-[3-[(diethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 519023-84-8  
 CMF C23 H25 F N4 O3




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 519023-86-0 CAPLUS  
 CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-2-(3-nitrophenyl)-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519023-87-1 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[3-  
[(diethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, hydrochloride  
(9CI) (CA INDEX NAME)



●x HCl

RN 519023-88-2 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[3-[[bis(1-methylethyl)amino]methyl]phenyl]-N-  
[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-,  
hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 519023-89-3 CAPLUS


10/824,917

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-2-(3-methylphenyl)-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 519023-90-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-([1,1'-biphenyl]-3-ylmethyl)-1,6-dihydro-5-hydroxy-2-(3-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519023-91-7 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 519023-92-8 CAPLUS


CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-N-[(2-methoxyphenyl)methyl]-2-(3-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)

10/824,917



RN 519023-93-9 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)-2-[3-(1-pyrrolidinylmethyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 519023-95-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[3-[(dimethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519023-94-0


CMF C21 H21 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 519023-96-2 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 519023-97-3 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3,4-difluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)






RN 519023-98-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]-(9CI) (CA INDEX NAME)



RN 519023-99-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(3-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-02-3 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-01-2


CMF C24 H26 F N5 O3

10/824,917



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 519024-04-5 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-(1-piperidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI)  
(CA INDEX NAME)


CM 1

CRN 519024-03-4  
CMF C24 H25 F N4 O3



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



10/824,917

RN 519024-05-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 519024-07-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[3-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-06-7


CMF C26 H30 Cl N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 519024-08-9 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 519024-09-0 CAPLUS  
 CN 4-Pyrimidinecarboxamide, N-[(2,4-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 519024-11-4 CAPLUS  
 CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-(1-pyrrolidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 519024-10-3  
 CMF C25 H28 N4 O5



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2


10/824,917



RN 519024-13-6 CAPLUS  
CN 4-Pyrimidinecarboxamide, 2-[3-[[bis(1-methylethyl)amino]methyl]phenyl]-N-  
[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-,  
trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 519024-12-5  
CMF C27 H34 N4 O5




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 519024-14-7 CAPLUS  
CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-N-[(3-methoxyphenyl)methyl]-  
6-oxo-2-[3-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

10/824,917




RN 519024-15-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(3-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-16-9 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 519024-19-2 CAPLUS


CN 4-Pyrimidinecarboxamide, 2-[3-[(dimethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-18-1

CMF C21 H22 N4 O3


10/824,917



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 519024-20-5 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[3-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519024-22-7 CAPLUS


CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)-2-[3-(1-piperidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-21-6


CMF C24 H26 N4 O3

10/824,917



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 519024-24-9 CAPLUS  
CN 4-Pyrimidinecarboxamide, 2-[3-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-  
1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)-, trifluoroacetate (salt)  
(9CI) (CA INDEX NAME)

CM 1

CRN 519024-23-8  
CMF C25 H29 N5 O3




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



10/824,917




RN 519024-26-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[3-[(dimethylamino)methyl]phenyl]-N-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-25-0


CMF C22 H20 F4 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 519024-28-3 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-(1-piperidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-27-2


CMF C26 H30 N4 O5

10/824,917



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 519024-30-7 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-2-[3-  
[(dimethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-,  
trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 519024-29-4  
CMF C23 H26 N4 O5



CM 2

CRN 76-05-1  
CMF C2 H F3 O2


10/824,917



RN 519024-32-9 CAPLUS  
CN 4-Pyrimidinecarboxamide, 2-[3-[(diethylamino)methyl]phenyl]-N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 519024-31-8  
CMF C25 H30 N4 O5




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 519024-33-0 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[3-[[2,4,5-trichlorophenyl]thio]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 519024-35-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519024-37-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,4-difluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519024-38-5 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 519024-39-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-40-9 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-chlorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-41-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)


10/824,917



RN 519024-43-2 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 519024-42-1  
CMF C24 H25 Cl N4 O3



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 519024-45-4 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-44-3  
CMF C23 H23 F N4 O3


10/824,917



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519024-47-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-46-5

CMF C25 H28 N4 O4




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/824,917




RN 519024-49-8 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, trifluoroacetate (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 519024-48-7


CMF C25 H28 N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 519024-51-2 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 519024-50-1

CMF C24 H25 Cl N4 O4




10/824,917



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519024-53-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, trifluoroacetate (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 519024-52-3


CMF C23 H23 F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 519024-54-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chlorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-55-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-difluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-57-8 CAPLUS


CN 4-Pyrimidinecarboxamide, 2-[4-[(dimethylamino)methyl]phenyl]-N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-56-7

CMF C23 H26 N4 O3


10/824,917



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519024-59-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[4-[(dimethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-58-9

CMF C22 H23 Cl N4 O3




CM 2

CRN 76-05-1

10/824,917

CMF C2 H F3 O2




RN 519024-61-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[4-[(diethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-60-3


CMF C24 H27 Cl N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 519024-63-6 CAPLUS


CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-62-5

CMF C23 H25 F N4 O3


10/824,917



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519024-65-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-64-7

CMF C25 H27 Cl N4 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/824,917




RN 519024-67-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 519024-66-9


CMF C24 H25 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 519024-68-1 CAPLUS

CN 4-Pyrimidinecarboxamide, N-([1,1'-biphenyl]-3-ylmethyl)-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-69-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 519024-70-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-69-2


CMF C25 H28 N4 O6



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 519024-71-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-72-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 519024-73-8 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-N-[(3-methoxyphenyl)methyl]-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



10/824,917




RN 519024-75-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-74-9


CMF C26 H31 N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 519024-77-2 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-76-1

10/824,917


CMF C25 H28 Cl N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519024-79-4 CAPIUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-78-3

CMF C24 H26 F N5 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/824,917




RN 519024-81-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-80-7


CMF C26 H30 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 519024-83-0 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-82-9

CMF C26 H30 N4 O4


10/824,917



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519024-85-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[1-(4-morpholinyl)ethyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 519024-84-1


CMF C24 H25 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/824,917


RN 519024-87-4 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(dimethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-86-3


CMF C21 H21 F N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 519024-89-6 CAPLUS


CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-88-5

CMF C25 H30 N4 O3


10/824,917



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519024-91-0 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-90-9

CMF C25 H30 N4 O4




CM 2

CRN 76-05-1


10/824,917

CMF C2 H F3 O2




RN 519024-92-1 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-93-2 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-N-[(4-methoxyphenyl)methyl]-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519024-95-4 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-2-[4-[(dimethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-94-3

CMF C23 H26 N4 O5


10/824,917



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519024-97-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519024-96-5

CMF C26 H31 N5 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/824,917



RN 519024-99-8 CAPLUS  
CN 4-Pyrimidinecarboxamide, 2-[4-[(dimethylamino)methyl]phenyl]-N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 519024-98-7  
CMF C23 H26 N4 O4



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 519025-01-5 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[1-(4-methyl-1-piperazinyl)ethyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 519025-00-4  
CMF C25 H28 F N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 519025-02-6 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519025-03-7 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2-chloro-4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)

10/824,917




RN 519025-04-8 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519025-05-9 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-N-[(2-methoxyphenyl)methyl]-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519025-07-1 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519025-06-0

CMF C25 H28 N4 O3


10/824,917



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519025-09-3 CAPIUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-[1-(1-piperidinyl)ethyl]phenyl]-, trifluoroacetate (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 519025-08-2

CMF C25 H27 F N4 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/824,917




RN 519025-11-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[1-(4-morpholinyl)ethyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519025-10-6


CMF C26 H30 N4 O6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519025-13-9 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[1-(4-methyl-1-piperazinyl)ethyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519025-12-8


CMF C27 H33 N5 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 519025-14-0 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 519025-15-1 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)






CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 519025-18-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 519025-19-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 519025-18-4

CMF C26 H30 N4 O5




10/824,917



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519025-21-9 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 519025-20-8


CMF C25 H28 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10/824,917

RN 519025-22-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-[1-(1-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 519025-23-1 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-[1-(1-piperidinyl)ethyl]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519025-22-0


CMF C27 H32 N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 519025-25-3 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519025-24-2


CMF C26 H31 N5 O5

10/824,917



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 519025-27-5 CAPLUS  
CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 519025-26-4  
CMF C25 H28 N4 O5




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 519030-68-3 CAPLUS


CN 4-Pyrimidinecarboxamide, N-([1,1'-biphenyl]-3-ylmethyl)-1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)

*Two diff.*

● x HCl

RN 519030-69-4 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 519030-70-7 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 519030-71-8 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3-chlorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 519030-72-9 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

10/824,917

RN 519030-73-0 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 519030-74-1 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 519030-75-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2-chloro-4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




10/824,917

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-N-(3-pyridinylmethyl)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519030-78-5


CMF C16 H13 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 519030-81-0 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-N-(2-pyridinylmethyl)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519030-80-9

CMF C16 H13 N5 O3






10/824,917

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/824,917

=> => d his

(FILE 'HOME' ENTERED AT 16:35:45 ON 14 SEP 2004)

FILE 'REGISTRY' ENTERED AT 16:35:57 ON 14 SEP 2004

L1 SCREEN 1840  
L2 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047  
L3 STRUCTURE UPLOADED  
L4 QUE L3 AND L1 NOT L2  
L5 20 S L4 SSS SAM  
L6 SCREEN 1840  
L7 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047  
L8 STRUCTURE UPLOADED  
L9 QUE L8 AND L6 NOT L7  
L10 8 S L9 SSS SAM  
L11 218 S L9 SSS FUL

FILE 'CAPLUS' ENTERED AT 16:44:02 ON 14 SEP 2004

L12 2 S L11

FILE 'CAOLD' ENTERED AT 16:44:48 ON 14 SEP 2004

=> s l11

L13 0 L11

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	171.05

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.40

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:45:05 ON 14 SEP 2004